UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Patient safety | Clinical trials | Inhibitor drugs | Heart attacks | Clinical outcomes
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2018, Volume 278, pp. 117 - 123
Journal Article
3.
Full Text
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2017, Volume 70, Issue 11, pp. 1368 - 1375
P2Y12 inhibition | cardiovascular death | secondary prevention | stroke | ischemic risk | myocardial infarction | P2Y | inhibition | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial Infarction - diagnosis | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Survival Rate - trends | Follow-Up Studies | Global Health | Humans | Middle Aged | Male | Treatment Outcome | Adenosine - administration & dosage | Dose-Response Relationship, Drug | Myocardial Infarction - drug therapy | Time Factors | Adenosine - analogs & derivatives | Thrombolytic Therapy - methods | Electrocardiography | Cause of Death - trends | Female | Aged | Ticagrelor | Myocardial infarction | Cardiovascular system | Heart | Cerebral infarction | Anticoagulants | Aspirin | Stroke | Heart attacks | Effectiveness | Risk | Cardiovascular disease | Patients | Thrombolysis | Bleeding | Disease prevention | Prevention | Confidence intervals | Survival analysis | Randomization | Ischemia | Infarction | Safety | Health risk assessment | Drug dosages
Journal Article
The Lancet (British edition), ISSN 0140-6736, 02/2018, Volume 391, Issue 10119, pp. 431 - 440
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Transluminal angioplasty | Product development | Polymer industry | Analysis | Surgical implants | Heart attacks | Angioplasty | Cyclin-dependent kinases | Clinical trials | Cardiovascular disease | Rapamycin | Chromium alloys | Patients | Thrombosis | Evidence-based medicine | Clinical outcomes | Coronary vessels | Implants | Polymer coatings | Polymers | Cardiology | Stents | Myocardial infarction | Embedding | Drug delivery | Biomedical materials | Randomization | Biocompatibility | Safety | Lesions | Thromboembolism | Complications | Blood vessels | Acute coronary syndromes | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
JAMA cardiology, ISSN 2380-6583, 07/2016, Volume 1, Issue 4, pp. 425 - 432
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Dyspnea - chemically induced | Stroke - prevention & control | Adenosine - adverse effects | Adenosine - analogs & derivatives | Adenosine - therapeutic use | Humans | Purinergic P2Y Receptor Antagonists | Quality of Life | Myocardial Infarction - prevention & control | Secondary Prevention | Hemorrhage - chemically induced | Ticagrelor
Journal Article
European heart journal. Cardiovascular pharmacotherapy, ISSN 2055-6837, 10/2019, Volume 5, Issue 4, pp. 200 - 206
Coronary artery disease | Post-myocardial infarction | Dual antiplatelet treatment | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Hemorrhage - mortality | Male | Drug Approval | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Ticagrelor - adverse effects | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Ticagrelor - administration & dosage | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Myocardial Infarction - diagnosis | Risk Assessment | Europe | Risk Factors | Treatment Outcome | Randomized Controlled Trials as Topic | Drug Labeling | Myocardial Infarction - drug therapy | Aged | Hemorrhage - chemically induced | Stroke | Heart attacks | Mortality | Coronary vessels | Adenosine diphosphate | Clinical trials | Cardiovascular disease | Cardiology | Index Medicus | Life Sciences | Original | Kardiologi | Post-myocardial | Cardiac and Cardiovascular Systems | infarction | aspirin | risk | prevention | events | Klinisk medicin | Clinical Medicine
Journal Article
JACC. Cardiovascular interventions, ISSN 1936-8798, 08/2019, Volume 12, Issue 16, pp. 1553 - 1561
Journal Article
European heart journal, ISSN 0195-668X, 04/2016, Volume 37, Issue 14, pp. 1133 - 1142
Antiplatelet therapy | Secondary prevention | P2Y12 inhibition | Ischaemic risk | Platelet inhibition | Ticagrelor | Coronary artery disease | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Risk Factors | Myocardial Ischemia - prevention & control | Male | Treatment Outcome | Secondary Prevention | Adenosine - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Female | Aged | Myocardial Ischemia - mortality | Hemorrhage - chemically induced | Index Medicus
Journal Article
The American heart journal, ISSN 0002-8703, 02/2019, Volume 208, pp. 81 - 90
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Chronic kidney failure | Apolipoproteins | Heart attack | Myocardial infarction | Intravenous administration | Renal function | Heart attacks | Cardiovascular disease | Family medical history | Apolipoprotein A | Randomization | Ischemia | Population | Safety | Drug dosages | Creatinine | Efflux | Kidneys | Medical imaging | Diabetes mellitus | Health risks | Disease control | Patients | Cholesterol | Glomerular filtration rate | Coronary vessels | Apolipoprotein A-I | Infarction | Diabetes | Kidney diseases | Cardiovascular diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2016, Volume 67, Issue 13, pp. 2262 - 2262
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2016, Volume 67, Issue 13, pp. 2146 - 2146
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A314 - A314
Journal Article
Atherosclerosis, ISSN 0021-9150, 2018, Volume 278, pp. 117 - 123
Journal Article
The Lancet (British edition), ISSN 0140-6736, 02/2018, Volume 391, Issue 10119, p. 431
Journal Article